📣 VC round data is live. Check it out!
- Public Comps
- Conmed
Conmed Valuation Multiples
Discover Conmed's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like MedicalSystem Technology, Shanghai Haohai, ChemoMetec, Artivion and more.
Conmed Overview
About Conmed
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Founded
1970
HQ

Employees
3.9K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialConmed Financials
Conmed reported last 12-month revenue of $1B and EBITDA of $274M.
In the same LTM period, Conmed generated $780M in gross profit, $274M in EBITDA, and $139M in net income.
Revenue (LTM)
Conmed P&L
In the most recent fiscal year, Conmed reported revenue of $1B and EBITDA of $276M.
Conmed is profitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 20%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
Conmed Stock Performance
Conmed has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Conmed's stock price is $33.85.
Conmed share price decreased by 5.2% in the last 30 days, and by 35.0% in the last year.
Conmed has an EPS (earnings per share) of $4.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | -2.3% | -5.2% | -4.3% | -35.0% | $4.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialConmed Valuation Multiples
Conmed trades at 1.3x EV/Revenue multiple, and 6.7x EV/EBITDA.
EV / Revenue (LTM)
Conmed Financial Valuation Multiples
As of June 3, 2026, Conmed has market cap of $1B and EV of $2B.
Conmed has a P/E ratio of 7.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Conmed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Conmed Margins & Growth Rates
Conmed decreased revenue by 1% and EBITDA by 1% in the last fiscal year.
In the most recent fiscal year, Conmed reported gross margin of 55%, EBITDA margin of 20%, and net margin of 10%.
Conmed Margins
Conmed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Conmed Operational KPIs
Conmed's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Conmed's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Conmed's Rule of X is 18% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Conmed Competitors
Conmed competitors include MedicalSystem Technology, Shanghai Haohai, ChemoMetec, Artivion, Mani Inc., Curiox Biosystems, Arcs Co, SEEGENE, Kuros Biosciences and Xvivo Perfusion.
Most Conmed public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 21.4x | 19.2x | 72.6x | 83.5x | |||
| 2.0x | 2.0x | 10.7x | 9.6x | |||
| 12.2x | 11.9x | 23.3x | 21.7x | |||
| 2.7x | 2.6x | 13.3x | 12.9x | |||
| 4.6x | 4.4x | 13.0x | 12.2x | |||
| 303.7x | 303.7x | (67.6x) | - | |||
| 0.2x | 0.2x | 3.7x | 3.8x | |||
| 1.9x | 1.9x | 7.4x | 7.7x | |||
This data is available for Pro users. Sign up to see all Conmed competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Conmed
Conmed has acquired 4 companies to date.
Last acquisition by Conmed was on August 1st 2022. Conmed acquired Biorez for $86M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Conmed
| Description | Biorez is a medical device company developing PLLA-based degradable polymer implants for soft tissue regeneration in orthopedics. Based in Montreal, Canada, it markets the FDA 510(k)-cleared L-C Ligament and biorez GRAFT for rotator cuff augmentation, implanted in 2,000+ procedures since 2015 to promote collagen synthesis over 12-24 months. | In2Bones is a Memphis-headquartered orthopedic implant manufacturer supplying devices and single-use instrumentation for upper and lower extremity surgeries. The portfolio includes plates, screws, nails, and external fixators for foot, ankle, hand, and wrist procedures performed by surgeons globally. Established in 2014, the company distributes products to over 40 countries through a network of 15 international subsidiaries. In2Bones emphasizes sterile-packed kits to streamline operating room efficiency, with FDA-cleared products adopted in more than 5,000 U.S. hospitals annually. | Buffalo Filter is a manufacturer of surgical smoke evacuation systems within Filtration Group's Life Sciences division. It produces wall-mounted and portable units like the Ultra series that capture 99.999% of plume particles during electrosurgery and laser procedures. Buffalo-headquartered since 1989, the company equips operating rooms in hospitals across North America and Europe with filters validated by OR nurses and surgeons. | SurgiQuest is an Orange, Connecticut-headquartered medical device company founded in 2006 that specializes in minimally invasive surgery tools, particularly its AirSeal insufflation system. This technology maintains stable pneumoperitoneum during laparoscopic procedures in bariatric, colorectal, gynecological, urologic, and general surgeries by creating an air curtain for unobstructed instrument access and smoke evacuation. SurgiQuest's innovations support procedures requiring precise visualization and have gained adoption in hospitals worldwide. |
| HQ Country | ||||
| HQ City | New Haven, CT | Memphis, TN | Lancaster, PA | - |
| Deal Date | 1 Aug 2022 | 4 May 2022 | 13 Dec 2018 | 16 Nov 2015 |
| Valuation | $86M | $260M | $365M | $265M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Conmed acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Conmed
| When was Conmed founded? | Conmed was founded in 1970. |
| Where is Conmed headquartered? | Conmed is headquartered in United States. |
| How many employees does Conmed have? | As of today, Conmed has over 3K employees. |
| Who is the CEO of Conmed? | Conmed's CEO is Patrick J. Beyer. |
| Is Conmed publicly listed? | Yes, Conmed is a public company listed on NYSE. |
| What is the stock symbol of Conmed? | Conmed trades under CNMD ticker. |
| When did Conmed go public? | Conmed went public in 1987. |
| Who are competitors of Conmed? | Conmed main competitors include MedicalSystem Technology, Shanghai Haohai, ChemoMetec, Artivion, Mani Inc., Curiox Biosystems, Arcs Co, SEEGENE, Kuros Biosciences, Xvivo Perfusion. |
| What is the current market cap of Conmed? | Conmed's current market cap is $1B. |
| What is the current revenue of Conmed? | Conmed's last 12 months revenue is $1B. |
| What is the current revenue growth of Conmed? | Conmed revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Conmed? | Current revenue multiple of Conmed is 1.3x. |
| What is the current EBITDA of Conmed? | Conmed's last 12 months EBITDA is $274M. |
| What is Conmed's EBITDA margin? | Conmed's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Conmed? | Current EBITDA multiple of Conmed is 6.7x. |
| What is the current FCF of Conmed? | Conmed's last 12 months FCF is $177M. |
| What is Conmed's FCF margin? | Conmed's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Conmed? | Current FCF multiple of Conmed is 10.4x. |
| How many companies Conmed has acquired to date? | As of June 2026, Conmed has acquired 4 companies. |
| What was the largest acquisition by Conmed? | $365M acquisition of Buffalo Filter on 13th December 2018 was the largest M&A Conmed has done to date. |
| What companies Conmed acquired? | Conmed acquired Buffalo Filter, SurgiQuest, In2Bones, and Biorez. |
| In how many companies Conmed has invested to date? | Conmed hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Conmed
Lists including Conmed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
